Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme
- 8 November 2005
- journal article
- case report
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 58 (1), 129-135
- https://doi.org/10.1007/s00280-005-0132-2
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI Journal of the National Cancer Institute, 2005
- Capecitabine and vinorelbine in elderly patients (≥65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)Annals Of Oncology, 2004
- Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping StrategiesJournal of Clinical Oncology, 2002
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expressionNature Genetics, 2001
- Clinical Pharmacokinetics of CapecitabineClinical Pharmacokinetics, 2001
- Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patientsCancer Chemotherapy and Pharmacology, 1999
- Clinical Pharmacokinetics of VinorelbineClinical Pharmacokinetics, 1996
- Pharmacokinetics of vinorelbine in manEuropean Journal of Clinical Pharmacology, 1992
- Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancerCancer, 1974